Search

Some strange new ways of raising money are starting to emerge - but would-be borrowers and lenders are still making sense of them.

Better, brighter, faster – that's where photonic lasers are trying to take us. A lay guide to the technology.

A politician's gaffe highlights the gender gap in science. Political action, not talk, is what's needed to close it.

A new proposal from the European Investment Fund seeks to accelerate the success of European technology transfer projects. A noble idea, says Mary Lisbeth D'Amico in her fortnightly column, but no one has yet stepped up to foot the bill.

OrthoMimetics, the first technology spin-out from the Cambridge-MIT Institute, Cambridge, UK, has begun its search for initial funding.

A British start-up is betting it has a better way for television networks to watch their viewers watching them.

We interview Andrew Newland, head of a venture capital consultancy with a long-term strategy of working with scientists and inventors.

The pace of forming academic spin-out companies picked up in the US in 2004 after a two-year slump, according to a survey released today.

Not all nanotechnology is hype. Carbon nanotubes are already inside a product near you.

Britain's privatised defence lab ties up with 7 universities, in a strategy to do more with fewer partners.

Tracking 15 key technologies, fraud in nanotechnology - and other insights into R&D management

A team of European researchers is applying a technology used to measure airflow over aircraft wings to improve human heart implants.

After the initial hype, the long haul through clinical development and the inevitable pitfalls, gene therapy is on the verge of becoming a commercial reality in Europe - ahead of the US.

The University of Cambridge is considering whether to make more cash available to invest in campus spin-off companies. And whatever decision it makes will come in for criticism…

Jo Taylor, head of venture capital at 3i Group, argues that universities are too quick to hit the spin-out button.

Universities are funding more campus companies. Richard L. Hudson on the rules of a very risky game.

Reports of incubators' demise were premature

For her latest fortnightly funding column, Mary Lisbeth D'Amico set out to find European seed funders. That was as easy as finding a needle in a haystack.

A spin-out from Sheffield that uses stem cells to help with conventional drug discovery is looking for investment to continue pre-clinical research on therapeutic applications and business development activities.